Pancreatic Cancer Research

ResearcherThe University of TokyoNo recent work listed

Takashi Sasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3352-0753; OpenAlex author ID A5041726256. Sources: OpenAlex.

Their work

Papers
19
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 7 papers · 2014: 5 papers · 2015: 3 papers

Papers 19

  1. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  2. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  3. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  4. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  5. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  6. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
  7. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Co-author DOI 10.1097/mpa.0000000000000139↗
  8. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  9. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  10. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  11. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  12. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  13. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  14. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  15. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  16. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31824f5970↗
  17. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  18. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Co-author DOI 10.1016/j.critrevonc.2010.05.007↗
  19. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiroyuki Isayama · 19 shared papers, 2011–2015 · strength 0.57
  2. Yousuke Nakai · 19 shared papers, 2011–2015 · strength 0.57
  3. Kazuhiko Koike · 18 shared papers, 2011–2015 · strength 0.55
  4. Minoru Tada · 18 shared papers, 2011–2015 · strength 0.53
  5. Hirofumi Kogure · 18 shared papers, 2011–2015 · strength 0.53
  6. Suguru Mizuno · 15 shared papers, 2011–2015 · strength 0.45
  7. Koji Miyabayashi · 14 shared papers, 2012–2015 · strength 0.43
  8. Hideaki Ijichi · 14 shared papers, 2012–2015 · strength 0.43
  9. Naminatsu Takahara · 13 shared papers, 2013–2015 · strength 0.41
  10. Tsuyoshi Hamada · 12 shared papers, 2013–2015 · strength 0.40
  11. Naoki Sasahira · 13 shared papers, 2011–2015 · strength 0.36
  12. Dai Mohri · 10 shared papers, 2013–2015 · strength 0.32
  13. Keisuke Yamamoto · 10 shared papers, 2011–2015 · strength 0.29
  14. Kazumichi Kawakubo · 8 shared papers, 2011–2015 · strength 0.22
  15. Saburo Matsubara · 6 shared papers, 2011–2015 · strength 0.17
  16. Kei Saito · 4 shared papers, 2014–2015 · strength 0.15
  17. Kazunaga Ishigaki · 2 shared papers, 2015 · strength 0.07
  18. Masao Omata · 3 shared papers, 2011–2012 · strength 0.07
  19. Tomotaka Saito · 2 shared papers, 2014–2015 · strength 0.07
  20. Yoshihiro Sakamoto · 1 shared paper, 2014 · strength 0.04
  21. Taku Aoki · 1 shared paper, 2014 · strength 0.04
  22. Norihiro Kokudo · 1 shared paper, 2014 · strength 0.04
  23. Hideo Yasunaga · 1 shared paper, 2014 · strength 0.03
  24. Tsuyoshi Takeda · 1 shared paper, 2015 · strength 0.03
  25. Takahiro Kishikawa · 1 shared paper, 2015 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.